NeuroSense Collaborates With Lonza To Identify Exosome-Based Biomarkers For Advance Neurodegenerative Disease Treatments And Diagnostics
NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration fieldLonza to develop, optimize, and qualify a method utili
Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug
Acumen Pharmaceuticals (ABOS) said Thursday that it has signed a collaboration agreement with healthcare manufacturing organization Lonza to develop and commercialize sabirnetug to treat Alzheimer's d
Lonza CEO Appointment to Be Well Received -- Market Talk
0735 GMT - Lonza Group's appointment of Wolfgang Wienand as its new CEO will likely get a favorable market reaction given that he is an external candidate who brings a wealth of experience in the drug
Lonza Group Appoints New CEO; Seeks Lifting of Trading Halt
Lonza Group (SGX:O6Z) appointed Wolfgang Wienand as chief executive, succeeding Albert Baehny, according to a Singapore bourse filing on Tuesday. Wienand, who will join the drug manufacturing company
Lonza Upgrades Guidance Following Roche Facility Acquisition -- Market Talk
1028 GMT - Lonza's agreement to acquire a U.S. manufacturing facility from Roche has led to a mid-term revenue guidance upgrade above consensus estimates, Jefferies analysts say in a research note. Th
Singaporean Shares Rise Tracking Global Gains; Top Glove's Shares Up 9% as Losses Shrink
Singapore shares finished marginally higher on Wednesday, following overnight gains in global markets. During the day, the benchmark Singapore Strait Times Index ranged between 3,174.13 and 3,188.06,
Lonza to Buy U.S. Manufacturing Facility From Roche For $1.2 Bln
By Andrea Figueras Lonza agreed to buy a manufacturing facility in the U.S. from Roche for around $1.2 billion in cash as it seeks to boost growth of its biologics division. The deal, due to close i
Lonza Group Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lonza Group (VTX:LONN) Full Year 2023 Results
Lonza Shares Rise on Sales, Earnings Beat
By David Sachs Lonza shares jumped Friday after the company posted consensus-beating sales and earnings. At 0858 GMT, shares in the Swiss life-sciences company were up 13% at CHF419.30 after rising
Lonza's Chair Succession Shouldn't Derail CEO Search -- Market Talk
Lonza Group's proposed chairman succession shouldn't affect a decision on a new CEO, which is key to rebuild confidence in the Swiss life-sciences company, Jefferies analysts say in a research note.
Lonza Names Heineken's Jean-Marc Huet as Next Chairman
Lonza Group has proposed Jean-Marc Huet, currently chairman of Dutch brewer Heineken, as its next chair to replace Albert Baehny.
Lonza Group's CEO Steps Down
Lonza Group's (SGX:O6Z) chief executive officer, Pierre-Alain Ruffieux, will step down from the role and leave the company at the end of the month by mutual agreement, according to a Monday bourse disclosure.
Lonza Group's Profit Declines 17.5% in H1 Despite Revenue Jump
Lonza Group (SGX:O6Z) posted a profit of 411 million Swiss francs in the first half of the year, 17.5% lower from the 498 million francs it posted a year earlier.
Lonza Group Profit Balloons 89% in H1 as Sales Rises 17%
03:08 AM EDT, 07/22/2022 (MT Newswires) -- Lonza Group (SGX:O6Z) posted a profit of 498 million Swiss francs ($514.9 million) in the first half of the year, an increase of 89.4% from the 263 million f
Lonza Group Investing $522 Million to Construct Drug Product Fill and Finish Facility in Switzerland
04:04 AM EDT, 07/01/2022 (MT Newswires) -- Lonza Group (SGX:O6Z) is investing 500 million Swiss francs ($522.2 million) to construct a large-scale commercial drug product fill and finish facility in S
Lonza Seen With Upside to Guidance Thanks to New Market Opportunities -- Market Talk
1019 GMT - Lonza's growth is underpinned by an increasing outsourcing trend among big pharma companies and the biotech industry, where a strong funding background is giving Lonza new customers,
Lonza's Extension of Sales-Growth Guidance Is an Upside -- Market Talk
1251 GMT - Lonza's prolonging of its sales-growth outlook to 2024 from 2023 at its capital markets day is an upside to most expectations, Jefferies says. The Swiss biotech and chemical company's
Lonza's Midterm Targets Support Growth Outlook, But Alone Won't Lift Consensus -- Market Talk
0937 GMT - Lonza's latest mid-term targets ahead of its capital markets day bode well for the Swiss biotech and chemical company's growth outlook, even if consensus expectations are likely to al
Lonza Provides New 2024 Targets; Anticipates "No Extraordinary" Capital Return -- Update
By Olivia Bugault Lonza Group AG on Tuesday provided new midterm financial targets and said it will continue to pay a dividend of 25% to 40% of its net income, but anticipates no extraordinar
Lonza Provides New 2024 Targets for Margins, Sales
By Olivia Bugault Lonza Group AG gave new midterm financial targets and set its strategic priorities for the coming years as it is hosting its capital-market day on Tuesday. The Swiss lif
No Data